stoxline Quote Chart Rank Option Currency Glossary
  
Incannex Healthcare Limited (IXHL)
2.1632  -0.047 (-2.12%)    02-06 11:42
Open: 2.24
High: 2.24
Volume: 35,617
  
Pre. Close: 2.21
Low: 2.16
Market Cap: 38(M)
Technical analysis
2025-02-06 11:50:35 AM
Short term     
Mid term     
Targets 6-month :  2.62 1-year :  3.06
Resists First :  2.25 Second :  2.62
Pivot price 1.83
Supports First :  1.78 Second :  1.5
MAs MA(5) :  1.99 MA(20) :  1.82
MA(100) :  1.96 MA(250) :  2.5
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  89.5 D(3) :  79.2
RSI RSI(14): 64.8
52-week High :  8.47 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IXHL ] has closed below upper band by 1.8%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.25 - 2.26 2.26 - 2.27
Low: 2.08 - 2.09 2.09 - 2.1
Close: 2.19 - 2.21 2.21 - 2.22
Company Description

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Headline News

Tue, 04 Feb 2025
IXHL - Incannex Healthcare Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Tue, 04 Feb 2025
Sleep Medicine Pioneer Joins Incannex's Revolutionary OSA Treatment Development - StockTitan

Thu, 23 Jan 2025
Incannex Reports Strong Results for Sleep Apnea Drug IHL-42X in Key Clinical Study - StockTitan

Thu, 14 Nov 2024
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewswire

Mon, 30 Sep 2024
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - GlobeNewswire

Tue, 10 Sep 2024
Incannex Healthcare lands $60 million financing deal - Green Market Report

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 18 (M)
Held by Insiders 1.342e+007 (%)
Held by Institutions 25.8 (%)
Shares Short 96 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.85e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -53 %
Return on Assets (ttm) 833.3 %
Return on Equity (ttm) -57 %
Qtrly Rev. Growth 12000 %
Gross Profit (p.s.) 0
Sales Per Share -52.14
EBITDA (p.s.) 5429.86
Qtrly Earnings Growth -1.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 7.59
Stock Dividends
Dividend 0
Forward Dividend 49200
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android